Analysts’ Weekly Ratings Changes for Insmed (INSM)

Several analysts have recently updated their ratings and price targets for Insmed (NASDAQ: INSM):

• 8/10/2026 – Insmed had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $195.00 price target on the stock, up from $185.00.
• 8/10/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright.
• 8/10/2026 – Insmed had its price target lowered by JPMorgan Chase & Co. from $179.00 to $175.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – Insmed had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $218.00 price target on the stock.
• 8/7/2026 – Insmed had its “outperform” rating reaffirmed by Evercore Inc. They now have a $170.00 price target on the stock.
• 8/7/2026 – Insmed had its price target lowered by Guggenheim from $207.00 to $205.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Insmed had its “buy” rating reaffirmed by UBS Group AG. They now have a $172.00 price target on the stock.
• 8/7/2026 – Insmed had its price target raised by Wells Fargo & Company from $161.00 to $169.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Insmed had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $175.00 price target on the stock.
• 7/28/2026 – Insmed had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $235.00 price target on the stock.
• 7/20/2026 – Insmed is now covered by BMO Capital Markets. They set an “outperform” rating and a $192.00 price target on the stock.
• 7/20/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright. They now have a $220.00 price target on the stock.
• 7/20/2026 – Insmed was upgraded by BMO Capital Markets to “strong-buy”.
• 7/17/2026 – Insmed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Insmed had its price target raised by Wells Fargo & Company from $160.00 to $161.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – Insmed had its “buy” rating reaffirmed by Guggenheim. They now have a $207.00 price target on the stock.
• 6/16/2026 – Insmed was given a new $192.00 price target by Mizuho.

Insider Activity

In related news, CFO Sara Bonstein sold 2,404 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the transaction, the chief financial officer owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. This represents a 3.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 1,806 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the completion of the sale, the insider owned 37,648 shares of the company’s stock, valued at $3,607,431.36. The trade was a 4.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 294,440 shares of company stock valued at $37,758,548. 2.10% of the stock is currently owned by company insiders.

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.